# Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine

> **NCT03527355** · PHASE2 · COMPLETED · sponsor: **International Vaccine Institute** · enrollment: 285 (actual)

## Conditions studied

- Typhoid

## Interventions

- **BIOLOGICAL:** Vi-DT
- **BIOLOGICAL:** FluQuadri™
- **OTHER:** 0.9% sodium chloride isotonic solution

## Key facts

- **NCT ID:** NCT03527355
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-18
- **Primary completion:** 2018-07-28
- **Final completion:** 2021-01-19
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2021-08-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03527355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03527355, "Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03527355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*